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Validation of a simple screening tool for early diagnosis of
advanced Parkinson’s disease in daily practice: the CDEPA
questionnaire
Pablo Martinez-Martin1,2, Jaime Kulisevsky1,3, Pablo Mir 1,4, Eduardo Tolosa1,5, Pilar García-Delgado6 and María-Rosario Luquin7
Early clinical diagnosis of advanced Parkinson’s disease (APD) may be difficult. This study aimed to validate a simple screening tool,
the CDEPA questionnaire (“Cuestionario De Enfermedad de Parkinson Avanzada” [Questionnaire for Advanced Parkinson’s
Disease]), for the identification of APD in daily practice. The study included 173 consecutively selected patients with PD (40% were
women, mean age was 68.4 ± 10.5 years), stratified according to the Hoehn and Yahr (HY) scale. The CDEPA questionnaire defined
APD as the presence of severe disability requiring help for activities of daily living (ADL), motor fluctuations with limitation or
inability to perform ADL, severe dysphagia, recurrent falls, or dementia. The diagnostic performance of the questionnaire was
assessed against the gold standard criterion based on clinical judgment. PD was categorized as advanced in 65 (38%) patients
when using the gold standard and in 109 (63%) patients when the CDEPA questionnaire was used. The CDEPA questionnaire and
the gold standard agreed moderately (kappa statistic of 0.48, P < 0.001). The CDEPA classified APD with a sensitivity of 97%;
specificity of 57%; total accuracy of 72.3%; and area under the curve (for a binary classifier) of 77.2%. Significant differences were
found between the groups created by the CDEPA in several usual PD evaluations (HY Scale, SCOPA Motor Scale, Non-motor
Symptoms Scale for PD, Clinical Impression of Severity Index for PD, Clinical Global Impression–Severity Scale, and Patient Global
Impression–Severity Scale). CDEPA showed satisfactory inter-rater agreement (kappa= 0.88) and test–retest concordance (kappa
0.83). In conclusion, the CDEPA questionnaire is a valid, reliable, and useful instrument for easily screening APD.
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INTRODUCTION
Affecting ~1% of individuals older than 60 years, Parkinson’s
disease (PD) often spans decades of a patient’s lifetime.1 While PD
has traditionally been considered as a motor disorder, it is now
recognized as a complex condition with diverse clinical features
that include neuropsychiatric and other non-motor manifestations
in addition to its motor symptomatology.2 The term advanced PD
(APD) is applied indistinctively to patients with long disease
duration (independently of clinical manifestations) or with motor
fluctuations and moderate or severe dyskinesia with disorders of
gait and equilibrium, or with neuropsychiatric symptoms or
cognitive impairment.3,4 In all these cases, motor and non-motor
symptoms are associated with loss of independence and
autonomy. At this stage, many symptoms do not improve with
conventional therapies, and other alternatives such as deep brain
stimulation (DBS), continuous subcutaneous apomorphine infu-
sion, or continuous infusion of levodopa/carbidopa intestinal gel
are required.5,6 Therefore, it is relevant to determine the patients’
clinical characteristics that can define APD and that make these
patients eligible or ineligible for advanced therapies.
In a previous prospective nationwide and after a three-round
Delphi study in Spain, the CDEPA questionnaire (Cuestionario De
Enfermedad de Parkinson Avanzada [Questionnaire for Advanced
Parkinson’s Disease]) were developed.7 This neurologist-based
questionnaire is a simple screening tool that could be useful to
identify patients with APD in the clinical setting. The presence of
any definitive symptom (severe disability means requiring help for
activities of daily living (ADL), presence of motor fluctuations with
limitations to perform basic ADL without help, severe dysphagia,
recurrent falls, or dementia) classifies the patient as APD. Probable
and possible levels of certainty for motor and non-motor
symptoms are also established (Table 1).
The aim of this study was to validate the CDEPA questionnaire.
Following completion of validation of the CDEPA in Spanish, a
cross-cultural adaptation and validation in other languages would
be useful to make this instrument available to other researchers
and to compare data from different samples and backgrounds.
RESULTS
A total of 173 patients with PD (40.4% women) with a mean age of
68.4 ± 10.5 years were included in the study. The distribution by
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HY stage was stage 1, 9.4%; stage 2, 33.3%; stage 3, 29.8%; stage 4,
22.2%; and stage 5, 5.3%. Most patients were retired (61%) and
had primary (47.9%) or secondary (23.7%) education. The mean
age at PD onset was 58.2 ± 10.4 years, at PD diagnosis was 59.1 ±
10.3 years, and at the beginning of treatment for PD was 59.7 ±
10.2 years. The mean duration of PD was 10.3 ± 5.8 years.
Descriptive data for the assessments applied in the study are
shown in the Supplementary material.
The number of patients diagnosed with APD and non-advanced
PD by the CDEPA instrument compared to clinical judgment (gold
standard) is shown in Table 2. Clinical judgment correlated
significantly with HY stage (ρ= 0.78, P < 0.001). According to the
CDEPA questionnaire, advanced PD was present in 109 (63.0%)
patients, whereas clinical judgment categorized 65 (37.6%)
patients as having APD. The degree of agreement in the
diagnostic accuracy of APD between the CDEPA questionnaire
and the gold standard based on clinical judgment was moderate
(kappa statistic 0.48, P < 0.001). The CDEPA instrument classified
APD versus non-advanced PD with a sensitivity of 96.9% (63/65
cases) and a specificity of 57.4%. The positive and negative
predictive values were 57.8% and 96.9%, respectively. The rate of
false positives and false negatives were 42.6% and 3.1%,
respectively. The diagnostic accuracy of the CDEPA questionnaire
was 72.3%. The area under the curve (ROC analysis for binary
classifiers) was 77.2%.
As shown in Table 3, in all cases where the CDEPA questionnaire
classified patients as APD, scores of the study rating scales (HY, S-
MS, NMSS, and CISI-PD) were significantly higher than in patients
classified as non-advanced.
When the characteristics of patients classified as true positives
(TP) (diagnosed as APD by the CDEPA questionnaire and the gold
standard) (n= 63) and false positives (FP) (classified as APD by the
CDEPA questionnaire but as non-advanced PD by the gold
standard) (n= 46) were compared, patients in the TP group were
significantly older, had a more advanced HY stage and duration of
disease, and showed higher scores in motor evaluation, ADL, and
motor fluctuations of the S-MS scale, as well as higher scores in
the domains of perceptual problems/hallucinations, attention/
memory, gastrointestinal tract, and total score of the NMSS scale.
All these differences were statistically significant. Also, significant
differences between the groups of TP and FP in the CISI-PD, CGIS,
and PGIS were observed, suggesting a more severe disease in the
TP group.
Regarding CDEPA reliability, the inter-rater agreement for 96
patients was 95.8% and kappa was 0.88 (95% CI: 0.75–1.0).
Furthermore, the test–retest concordance for 46 patients was
93.5% with a kappa equal to 0.83 (95% CI: 0.64–1.0).
DISCUSSION
Identification of disease severity in PD patients on clinical grounds
in daily practice is important to outline a rational treatment plan in
order to obtain maximum benefit from conventional therapies or
to recommend alternative therapies in patients with late-stage PD.
However, agreement among neurologists regarding the clinical
characteristics that patients with APD should exhibit has not yet
Table 1. Diagnostic criteria of advanced Parkinson’s disease using the CDEPA questionnaire
Domain Level of certainty of the symptoms
Definitivea Probableb Possiblec
General characteristics Evolution time (around 10 years)
Disability Requiring help to perform daily living
activities
Limitation to perform basic




Motor fluctuations with an off time
>25%, with limitation to perform the
basic activities without requiring help
Functional disability due to

















Dementia Hallucinations without preserved
insight
Moderate–severe apathy




All symptoms are scored as either “yes” (presence) or “no” (absence) [7]
aThe presence of a definitive symptom makes the diagnostic of advanced Parkinson’s disease
bThe association of two symptoms from different areas (general characteristics, disability, motor symptoms related to treatment, etc.) of the probable level
places the case as definitive
cThe association of one motor or non-motor symptom from the disease-related areas plus one symptom of the neuropsychiatric and cognitive areas in the
possible level places the case as probable
Table 2. Classification of patients in the advanced and non-advanced
groups according to the CDEPA instrument versus clinical judgment
CDEPA instrument Clinical judgment (gold standard) Total
Advanced PD Non-advanced PD
Advanced PD 63 46 109 (63.0)
Non-advanced PD 2 62 64 (37.0)
Total 65 (37.6) 108 (62.4) 173 (100)
No. (%)
Sensitivity was 96.9%; specificity was 57.4%; false positives were 42.6%;
false negatives were 3.1%; positive predictive value was 57.8%; negative
predictive value was 96.9%; total accuracy was 72.3%
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been reached.3 Late-stage PD is dominated by loss of autonomy
due to motor and non-motor symptoms with a decrease in
levodopa response,8 but studies on APD are limited.
In a previous study carried out by our group, a consensus on the
definition of APD using a three-round Delphi methodology was
reached.7 APD was defined as the disease stage in which certain
symptoms and complications are present, with a detrimental
influence on the overall patient’s health condition and with a poor
response to conventional treatments. Definitive symptoms were
considered for those whose presence, even when isolated, were
enough to classify PD as APD, which included severe disability,
motor fluctuations with limitation or inability to perform ADL
without assistance, severe dysphagia, recurrent falls, or dementia.
Probable and possible levels of certainty were also established
(Table 1). In the studies performed by Coelho et al.,9,10 including
the Barcelona and Lisbon cohort of 50 patients, postural instability
causing frequent falls and prominent dysphagia were found to
dominate the motor syndrome in late-stage PD. Dementia was
also present in 50% of the patients in whom lack of tremor and
absence of depression were independently associated with
dementia. In addition, a high handicap score in this cohort
measured by the London Handicap Score was mostly driven by
the presence of dementia.10
Because a criterion like that defined in the CDEPA questionnaire
has not been found in previously published studies, it was
proposed to accept the neurologist’s clinical judgment as the best
available benchmark (gold standard) to determine the presence or
absence of APD. Clinical judgment (Table 4) was established after
the clinician had thoroughly examined the patient using a battery
of validated scales for severity evaluation in PD.11,12 Adequacy
criteria for the selection of clinical judgment as the gold standard
was supported by a high-positive correlation with HY stage
classification.
The ability of the questionnaire to distinguish between
advanced and non-advanced PD was assessed by comparison
with the gold standard. The sensitivity of the CDEPA questionnaire
Table 3. Diagnosis established by the CDEPA instrument and scores of the study assessments
Diagnosis with the CDEPA questionnaire
Advanced
mean ± SD (95% CI)
Non-advanced
mean ± SD (95% CI)
P value
Hoehn and Yahr stage 3.3 ± 0.9 (3.1–3.5) 2.0 ± 0.7 (1.8–2.2) 0.001
SCOPA motor scale
Examination (motor evaluation) 16.1 ± 6.4 (14.8–17.3) 6.6 ± 4.1 (5.6–7.7) 0.001
Activities of daily living 10.3 ± 4.5 (9.4–11.2) 2.9 ± 2.6 (2.2–3.5) 0.001
Dyskinesias 2.2 ± 1.9 (1.8–2.6) 0.5 ± 1.2 (0.1–0.8) 0.001
Motor fluctuations 2.7 ± 1.6 (2.4–3.0) 0.6 ± 1.1 (0.4–0.9) 0.001
Total scores 30.8 ± 11.72 (28.6–33.0) 10.6 ± 7.1 (8.8–12.35) 0.001
Non-motor symptoms scale
Cardiovascular 1.2 ± 2.2 (0.8–1.7) 0.5 ± 1.3 (0.2–0.9) 0.003
Sleep/fatigue 11.4 ± 8.7 (9.8–13.1) 5.3 ± 5.7 (3.9–6.7) 0.001
Mood/cognition 12.4 ± 15.3 (9.5–15.3) 4.8 ± 11.2 (2.0–7.6) 0.001
Perceptual problems/hallucinations 1.9 ± 4.3 (1.1–2.7) 0.4 ± 1.8 (−0.1−0.8) 0.001
Attention/memory 5.9 ± 8.0 (4.4–7.4) 2.6 ± 5.1 (1.3–3.9) 0.001
Gastrointestinal tract 5.8 ± 6.3 (4.6–7.0) 2.3 ± 3.3 (1.5–3.1) 0.001
Urinary function 9.8 ± 8.7 (8.1–11.4) 4.8 ± 6.6 (3.2–6.4) 0.001
Sexual function 4.4 ± 6.1 (3.2–5.5) 3.2 ± 5.8 (1.8–4.7) 0.457
Miscellaneous 8.2 ± 7.5 (6.8–9.6) 4.8 ± 4.9 (3.6–6.0) 0.005
Total score 60.9 ± 41.0 (53.1–68.7) 29.0 ± 29.6 (21.4–36.2) 0.001
Clinical Impression of severity index for PD 13.0 ± 4.0 (12.2–13.8) 5.1 ± 3.2 (4.3–6.0) 0.001
Table 4. Parkinson’s disease (PD) clinical stage based on the neurologist’s clinical judgment (gold standard)
Clinical stage Clinical characteristics
Initiala Very mild clinical manifestations; absence of disability; and no need of pharmacologic treatment or only initial therapy at low effective
doses
Milda Mild clinical and functional manifestations; minimal or no complications; and satisfactory response to conventional pharmacologic
therapy
Moderatea Moderate clinical manifestations and disability; good response; some complications are present, although not satisfactory to the
conventional pharmacologic therapy
Advancedb Severe clinical manifestations and disability; severe motor and non-motor complications; partial poor response to conventional
pharmacologic therapy
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for the identification of APD was very high. In 97% of cases in
which the gold standard indicated that the patient had APD, the
CDEPA questionnaire coincided. The specificity was 57.4%.
Misclassfication occurred in 48 cases (22.7%) (46 false positives
and 2 false negatives). However, statistically significant differences
were found between scores of all measures in the study using the
groups of advanced and non-advanced PD identified by the
CDEPA questionnaire. The performance of clinical judgment in
relation to PD global severity evaluation according to the study
assessments was also analyzed as a further measure of validity of
the CDEPA instrument. Overall, the performance of the gold
standard for the recognition of APD was similar to CDEPA. With
regard to the CISI-PD, which has been shown to be the scale most
closely correlated to any other variable measuring the severity of
PD manifestations and functional disability,12 the cutoff point for
the total CISI-PD score to discriminate advanced versus non-
advanced patients according to the CDEPA questionnaire was 9.
The equivalent cutoff point was 6 for the CGIS.
Discrepancy between the results of the CDEPA questionnaire
and the gold standard was also explained when the characteristics
of true positives and false positives were compared. It was
observed that patients categorized as false positives were not as
markedly affected as the patients categorized as true positives,
suggesting that (1) they actually could be false positives for
advanced PD because their disease is not advanced or (2) a
greater subtleness than the “routine” clinical criterion for
detection of APD is required (which might be provided by
CDEPA). In this case, they would not be false positives, but true
cases identified by CDEPA. A similar situation was reported in the
study conducted by Stacy et al.13 that identified wearing-off signs
and symptoms, in which the self-assessment patient questionnaire
was more sensitive (57.1%) than the clinical assessment question
(29.4%). Most importantly, only 3% of the APD cases according to
the gold standard were lost by the CDEPA, whose high sensitivity
and negative predictive values characterize this questionnaire as a
potentially powerful screening instrument for the detection of
APD. In addition, the inter-rater and test–retest reliability were
satisfactory.
Limitations of the study include a lack of comparable measures
for the criteria assessed with the CDEPA instrument, a small
sample size partly due to advanced therapies (DBS, apomorphine,
and Duodopa) as an exclusion criterion, and findings restricted to
Spanish patients.
In conclusion, the CDEPA questionnaire is quick and easy to
administer, suggesting that it could be integrated in PD outpatient
clinics as a useful tool for screening PD patients, particularly due to
the high sensitivity observed when classifying the advanced stage
of the disease. However, a large-scale study including more
patients with PD will help provide more extensive data to support
the external validity of this instrument.
METHODS
Design
A cross-sectional, observational, and multicenter study was conducted
between 1 January 2015 and 8 July 2016. This study was performed in the
outpatient clinics of the Departments of Neurology from 24 hospitals
throughout Spain. Neurologists from these centers attended to patients
with PD and voluntarily accepted to take part in the study. The primary
objective of the study was to analyze the discriminative capacity of the
CDEPA questionnaire for the diagnosis of APD with the neurologist’s
clinical judgment selected as the “gold standard.” For this reason, values
≥80% for sensitivity and negative predictive, and moderate or higher
agreement with the gold standard were deemed acceptable.
The study protocol was approved by the Ethics Committee of the
participating centers. The study was conducted in accordance with the
standards of good clinical practice and the current revision of the
Declaration of Helsinki. Written informed consent to participate was
obtained from all patients. Personal data were anonymized.
Study participants
We enrolled consecutive patients with PD with at least 2 years of evolution
at any stage of the Hoehn and Yahr (HY) scale;14 patients of any age,
gender, and mental condition; caregivers of those patients who met the
aforementioned criteria, but had limited ability to follow the interview by
themselves; and patients who signed the informed consent. Patients who
received DBS or any surgery for advanced PD, continuous subcutaneous
apomorphine infusion, or continuous infusion of levodopa/carbidopa
intestinal gel were excluded as they had previously been classified as
patients with advanced PD.
Procedures and assessments
Data were recorded during a single routine clinical visit. Each patient was
visited by two independent neurologists (neurologist #1 and neurologist #2).
Neurologist #1 assessed the eligibility criteria and invited the patient to
participate in the study. Those patients who signed the informed consent
underwent a clinical examination and were administered a battery of general
and specific tests including the HY staging scale,14 the Scale for Outcomes in
PD (SCOPA) Motor Scale (S-MS),15 the Non-Motor Symptoms Scale (NMSS) for
Parkinson’s disease,16 the Clinical Impression of Severity Index for Parkinson’s
disease (CISI-PD),17,18 the Clinical Global Impression–Severity Scale (CGIS),19
and the Patient Global Impression–Severity Scale (PGIS).20,21
Briefly, the S-MS contains 21 items in three sections, with possible scores
ranging from 0 to 42 for examination, 0 to 21 for ADL, and 0 to 12 for
complications (0 to 6 for dyskinesias and 0 to 6 for fluctuations). The NMSS
has 30 items and 9 domains: cardiovascular (2 items), sleep/fatigue (4
items), mood/cognition (6 items), perceptual problems/hallucinations (3
items), attention/memory (3 items), gastrointestinal tract (3 items), urinary
function (3 items), sexual function (2 items), and miscellaneous (4 items).
Each item is scored based on a multiple of severity (from 0 to 3) and
frequency (from 1 to 4). The CISI-PD is based on the impression of the
clinician about the severity of four outstanding PD aspects: motor signs,
disability, motor complications, and cognitive status. Each item domain is
scored from 0 (normal) to 6 (very severe), with a total score ranging
between 0 and 24. The CGIS includes seven response options from
1 “normal, not at all ill” to 7 “among the most extremely ill patients” and
the 6-point PGIS scores: 1 as “normal”, 2–3 as “mild”, 4 as “moderate”, and
5–6 as “severe”.
At the end of the interview, neurologist #1 classified PD as advanced or
non-advanced (gold standard) and answered the question “In which stage
do you consider that this patient can be categorized?” according to pre-
established criteria (for initial, mild, moderate, advanced, and late-stage)
defined by the research group (Table 4). Advanced PD was defined as “a
phase with severe clinical manifestations, disability, and motor and non-
motor complications with poor response to conventional pharmacologic
therapy (Table 4).”
Thereafter, neurologist #2, who was blinded to the results of the
interview and the clinical judgment of neurologist #1, administered the
CDEPA questionnaire7 during an immediately subsequent clinical encoun-
ter and made a diagnosis of advanced or non-advanced PD based only on
this questionnaire. Details on the contents of the CDEPA questionnaire are
shown in Table 1.
Testing of the inter-rater CDEPA reliability was carried out by two
neurologists who independently applied the questionnaire. A second
application, to explore the test–retest reliability, was performed 2–4 weeks
after the first application.
Data collection
For each patient, the following data were recorded: age, gender; working
status (employee, sick leave, retired); education level (no studies, primary
studies, secondary studies, university); age at the onset of symptoms; age
at diagnosis of PD; duration of PD; age at starting a specific treatment for
PD; current treatment for PD; and other pharmacologic treatment. Also, HY
stage and the results of the S-MS, NMSS, CISI-PD, CGIS, and PGIS
questionnaires were recorded in the “on” state. Patients were finally
classified as advanced or non-advanced PD according to the neurologist’s
clinical judgment and results of the CDEPA questionnaire.
Statistical analysis
The patients were selected by consecutive sampling over the study period.
It was planned that 12 patients stratified by HY stages (stages 1 and 2, 2
patients; stage 3, 5 patients; stages 4 and 5, 5 patients) would be recruited
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by each participating neurologist. A difference of 15% between the
expected 40% APD in moderate/severe HY and the identified 25% in the
real world, 100 patients in HY 3–5 would reach a 0.91 power. Categorical
variables are expressed as frequencies and percentages, and continuous
variables as measures of central tendency. Categorical variables were
compared with the Fisher’s exact test. Because of the ordinal origin and
non-normal distribution of data, groups of continuous data were
compared with the Mann–Whitney U test or the Kruskal–Wallis test. The
relationship between two continuous variables was assessed with the
Spearman’s rank-order correlation coefficient, rho (ρ). The validity of the
CDEPA questionnaire for the diagnosis of APD was assessed by means of
the characteristic 2 × 2 table in front of the gold standard (classification by
neurologist #1). Sensitivity, specificity, and positive and negative predictive
values were calculated. The agreement level between the CDEPA and the
gold standard was checked by the kappa index, judging the results
according to Landis and Koch scale22 (0.00–0.20: negligible, 0.21–0.40:
weak, 0.41–0.60: moderate, 0.61–0.80: substantial, 0.81–1.00: almost
perfect). Statistical significance was set at p < 0.05. CDEPA inter-rater and
test–retest reliability were analyzed with the kappa statistic. Statistical
analyses were performed by means of the Statistical Analysis Systems (SAS
Institute, Cary, NC, USA) version 9.1.3 Service Pack.
Data availability
The data sets generated during and/or analyzed during the current study
are available from the corresponding author on reasonable request.
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